Dermatology

These phase 3 data on delgocitinib cream (Anzupgo) 20 mg/g highlight the drug’s potential for adolescents aged 12 years and older with chronic hand eczema (CHE).

Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.

Kernizan discusses winning the 2024 Society for Pediatric Dermatology Medical Student Mentorship Award and getting into pediatric dermatology as a student.

In this analysis, investigators demonstrated that risankizumab led to improvements in palmoplantar pustulosis (PPP) that continued through to Week 68.

These data point to the necessity of quality and usability when using smartphone photographs of skin conditions in emergency departments.

In this interview, Druskovich highlights her experiences being mentored through the Society for Pediatric Dermatology’s Medical Student Mentorship Award.

These data highlight the unique burdens faced by patients with generalized pustular psoriasis (GPP) compared to those of patients with psoriasis vulgaris.

Participants in a phase 3 OLE had a mean monthly attack rate of 0.08.

These data provide a potential option for those suffering from hidradenitis suppurativa, as off-label treatment with botulinum toxin type X led to positive findings in patients.

On Feb. 26, 2025, Arcutis Biotherapeutics announced the FDA's acceptance of their sNDA for roflumilast cream 0.05% in AD for children aged 2 to 5 years.

Sebetralstat has a PDUFA date of June 12, 2025, for treating HAE in patients 12 years and older.

These data point to increasing omega-3 consumption as a potential preventive strategy against atopic dermatitis.

In this analysis, investigators sought evaluate the effectiveness and safety of adding low-dose oral minoxidil to the standard anti-inflammatory treatment of lichen planopilaris.

These data suggest that psoriasis treatment algorithms may benefit younger patients if they implement a step-down rather than step-up approach to biologic use.

Ahead of AAAAI 2025, HCPLive spoke with Jaroenpuntaruk about varying hypersensitivity reactions in patients with atopic diseases on biologics.

These findings highlight the prevalence of atopic dermatitis among adults in France, as well as the different factors associated with various disease profiles.

These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.

Our top 5 headlines included a new approval for atopic dermatitis, expert consensus on anaphylaxis care, and the end of the semaglutide shortage.

Investigators in China developed a patch test designed for hair care products tailored to clinical needs such as those of patients with conditions like alopecia areata.

These data suggest therapeutic modulation of IL-23 inhibitors for psoriasis in those who have shown stability may be a legitimate strategy to ensure efficacy and safety.

A study analyzed hypersensitivity reactions to biologics for atopic diseases, highlighting reaction types, severity, and biologic discontinuation rates.

In new data to be presented at AAAAI, the therapy was well-tolerated in people as young as 2 years old.

These data were the result of a new network meta-analysis looking specifically at children with eczema, highlighting the hierarchy of effectiveness among systemic drugs.

By week 52, remibrutinib and placebo-to-remibrutinib groups had similar levels of urticaria control.

Alpyn’s Investigational New Drug application’s clearance by the FDA for the new Zabalafin Hydrogel for atopic dermatitis follows positive phase 2a clinical findings.